Modelling of the 177mLu/177Lu radionuclide generator

Journal Article (2020)
Author(s)

Rupali Bhardwaj (TU Delft - ChemE/Catalysis Engineering, TU Delft - RST/Applied Radiation & Isotopes)

Hubert Th Wolterbeek (TU Delft - RST/Applied Radiation & Isotopes)

A. G. Denkova (TU Delft - RST/Applied Radiation & Isotopes)

P. Serra-Crespo (TU Delft - RST/Applied Radiation & Isotopes)

Research Group
RST/Applied Radiation & Isotopes
Copyright
© 2020 R. Bhardwaj, H.T. Wolterbeek, A.G. Denkova, P. Serra Crespo
DOI related publication
https://doi.org/10.1016/j.apradiso.2020.109261
More Info
expand_more
Publication Year
2020
Language
English
Copyright
© 2020 R. Bhardwaj, H.T. Wolterbeek, A.G. Denkova, P. Serra Crespo
Research Group
RST/Applied Radiation & Isotopes
Volume number
166
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

In order to determine the potential of 177mLu/177Lu radionuclide generator in 177Lu production it is important to establish the technical needs that can lead to a clinically acceptable 177Lu product quality. In this work, a model that includes all the processes and the parameters affecting the performance of the 177mLu/177Lu radionuclide generator has been developed. The model has been based on the use of a ligand to complex 177mLu ions, followed by the separation of the freed 177Lu ions. The dissociation kinetics of the Lu-ligand complex has been found to be the most crucial aspect governing the specific activity and 177mLu content of the produced 177Lu. The dissociation rate constants lower than 1*10-11 s-1 would be required to lead to onsite 177Lu production with specific activity close to theoretical maximum of 4.1 TBq 177Lu/mg Lu and with 177mLu content of less than 0.01%. Lastly, the calculations suggest that more than one patient dose per week can be supplied for a period of up to 7 months on starting with the 177mLu produced using 3 g Lu2O3 target with 60% 176Lu enrichment. The requirements of the starting 177mLu activity production needs to be adapted depending on the required patient doses, and the technical specifications of the involved 177mLu-177Lu separation process.